Quick Takeaways
- RCKT - ROCKET PHARMACEUTICALS, INC. has 24 insiders with reported activity on this page.
- Net insider value flow over the last year: -$398,309.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 24 Insiders of ROCKET PHARMACEUTICALS, INC.
- Symbol
- RCKT, RCKTW on Nasdaq
- Location
- New York, NY
What Changed
- Buy value: $68,500; sell value: $466,809.
- Net share flow: -107,157.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$398,309.
Buys
$68,500
Shares: 20,000
Insiders: 1
Sells
$466,809
Shares: 127,157
Insiders: 6
Net
-$398,309
Shares: -107,157
Insiders: -5
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 36,781 | $0 | $122,040 | -$122,040 |
| 3-6 | 10,000 | 11,553 | $34,400 | $34,463 | -$62.6 |
| 6-9 | 10,000 | 64,368 | $34,100 | $221,720 | -$187,620 |
| 9-12 | 0 | 14,455 | $0 | $88,586 | -$88,586 |
ROCKET PHARMACEUTICALS, INC. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | Director, Other*, 10%+ Owner | $100,686,510 | Mixed | 19 Sep 2025 | ||
| Roderick Wong | Director, 10%+ Owner | $44,689,444 | Mixed | 18 Jun 2025 | ||
| Gaurav Shah | Ceo | $8,658,782 | -$117,545 | -1.3% | Mixed | 18 Feb 2026 |
| Kinnari Patel | President, Head of R&D and Chief Operating Officer | $6,417,297 | -$14,142 | -0.22% | Mixed | 20 May 2025 |
| Martin Louis Wilson | General Counsel | $4,301,532 | -$101,440 | -2.3% | Mixed | 18 Feb 2026 |
| Jonathan David Schwartz | Chief Science & Gene Therapy Officer | $2,692,124 | -$64,338 | -2.3% | Mixed | 18 Nov 2025 |
| Gotham Makker | Director | $2,545,450 | Mixed | 18 Jun 2025 | ||
| Aaron Ondrey | Chief Financial Officer | $2,394,410 | -$4,257 | -0.18% | Mixed | 03 Jul 2025 |
| Christopher James Stevens | Chief Operating Officer | $1,782,690 | Mixed | 11 Feb 2026 | ||
| Mark Andrew White | General Manager, Commercial Affairs | $1,560,177 | Mixed | 31 Oct 2024 | ||
| Syed Ali-Aamir Rizvi | Chief Medical Officer | $1,549,921 | Mixed | 11 Feb 2026 | ||
| Sarbani Chaudhuri | Chief Commercial & Medical Affairs Officer | $1,083,608 | Mixed | 11 Feb 2026 | ||
| Carlos Garcia-Parada | Chief Financial Officer | $1,068,080 | Mixed | 14 Feb 2022 | ||
| John Militello | Vice President of Finance, Treasurer, Principal Accounting Officer | $753,818 | -$165,087 | -18% | Mixed | 18 Feb 2026 |
| Mikael Dolsten | Director | $454,105 | Mixed | 18 Jun 2025 | ||
| Piratip Pratumsuwan | Director | $411,061 | Mixed | 18 Jun 2025 | ||
| Keith Woods | Director | $360,118 | Mixed | 13 Jun 2024 | ||
| David P. Southwell | Director | $354,806 | Mixed | 18 Jun 2025 | ||
| Peter Fong | Director | $174,932 | Mixed | 24 Sep 2025 | ||
| Elisabeth Bjork | Director | $172,000 | +$68,500 | +66% | Filing P/S | 02 Jan 2026 |
| Pedro P. Granadillo | Director | $134,131 | Mixed | 18 Jun 2025 | ||
| Naveen Yalamanchi | Director | $103,965 | Mixed | 13 Jun 2024 | ||
| Carsten Boess | Director | $73,518 | Mixed | 18 Jun 2025 | ||
| Fady Ibraham Malik | Director | $73,518 | Mixed | 18 Jun 2025 |
Top shareholders of ROCKET PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP |
3/4/5
13F
|
Director, Other*, 10%+ Owner · Company |
—
mixed-class rows
|
21,763,079
mixed-class rows
|
$100,686,510 | — | 19 Sep 2025 | |
| Roderick Wong |
3/4/5
|
Director, 10%+ Owner |
17%
|
18,236,124
|
$44,689,444 | — | 18 Jun 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
7.8%
|
8,544,423
|
$29,990,925 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
7.2%
|
7,906,071
|
$27,750,309 | — | 31 Dec 2025 | |
| CITIGROUP INC |
13F
|
Company |
4.8%
|
5,246,349
|
$18,414,685 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
3.6%
|
3,941,377
|
$13,834,233 | — | 31 Dec 2025 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.7%
|
2,992,735
|
$10,504,500 | — | 31 Dec 2025 | |
| Monaco Asset Management SAM |
13F
|
Company |
2.7%
|
2,987,296
|
$10,485,409 | — | 31 Dec 2025 | |
| MAVERICK CAPITAL LTD |
13D/G
13F
|
Company |
2.3%
|
2,513,110
|
$9,549,818 | -$22,232,671 | 31 Dec 2025 | |
| Newtyn Management, LLC |
13F
|
Company |
2.4%
|
2,650,000
|
$9,301,500 | — | 31 Dec 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
2.4%
|
2,640,518
|
$9,268,218 | — | 31 Dec 2025 | |
| Gaurav Shah |
3/4/5
|
CEO |
—
mixed-class rows
|
2,322,941
mixed-class rows
|
$8,658,782 | -$117,545 | 18 Feb 2026 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
|
— |
0.9%
|
1,004,476
|
$7,895,181 | -$48,317,346 | 30 May 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
2%
|
2,131,929
|
$7,483,071 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.9%
|
2,120,269
|
$7,443,495 | — | 31 Dec 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
1.7%
|
1,864,651
|
$6,544,925 | — | 31 Dec 2025 | |
| Kinnari Patel |
3/4/5
|
President, Head of R&D and Chief Operating Officer |
—
mixed-class rows
|
745,842
mixed-class rows
|
$6,417,297 | -$14,142 | 20 May 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.6%
|
1,784,921
|
$6,265,073 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.6%
|
1,700,631
|
$5,969,215 | — | 31 Dec 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
1.5%
|
1,586,076
|
$5,567,127 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
1.4%
|
1,475,624
|
$5,179,442 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
—
mixed-class rows
|
1,611,480
mixed-class rows
|
$4,569,135 | — | 31 Dec 2025 | |
| Martin Louis Wilson |
3/4/5
|
General Counsel |
—
mixed-class rows
|
1,150,187
mixed-class rows
|
$4,301,532 | -$101,440 | 18 Feb 2026 | |
| Opaleye Management Inc. |
13F
|
Company |
0.87%
|
955,000
|
$3,352,050 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.86%
|
944,873
|
$3,318,000 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.86%
|
936,594
|
$3,287,444 | — | 31 Dec 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.81%
|
881,249
|
$3,093,184 | — | 31 Dec 2025 | |
| Jonathan David Schwartz |
3/4/5
|
Chief Science & Gene Therapy Officer |
—
mixed-class rows
|
418,746
mixed-class rows
|
$2,692,124 | -$64,338 | 18 Nov 2025 | |
| Deutsche Girozentrale DekaBank |
13F
|
Individual |
0.08%
|
89,700
|
$2,658,000 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.68%
|
744,286
|
$2,612,444 | — | 31 Dec 2025 | |
| Prosight Management, LP |
13F
|
Company |
0.68%
|
743,942
|
$2,611,236 | — | 31 Dec 2025 | |
| Gotham Makker |
3/4/5
|
Director |
—
mixed-class rows
|
1,037,149
mixed-class rows
|
$2,545,450 | — | 18 Jun 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.64%
|
703,528
|
$2,469,383 | — | 31 Dec 2025 | |
| Aaron Ondrey |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
262,815
mixed-class rows
|
$2,394,410 | -$4,257 | 03 Jul 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.57%
|
618,654
|
$2,171,476 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.55%
|
602,580
|
$2,115,056 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.53%
|
579,507
|
$2,034,070 | — | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.46%
|
507,909
|
$1,782,761 | — | 31 Dec 2025 | |
| Christopher James Stevens |
3/4/5
|
Chief Operating Officer |
—
mixed-class rows
|
562,166
mixed-class rows
|
$1,782,690 | — | 11 Feb 2026 | |
| Walleye Capital LLC |
13F
|
Company |
—
mixed-class rows
|
783,676
mixed-class rows
|
$1,759,562 | — | 31 Dec 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.44%
|
475,800
|
$1,670,058 | — | 31 Dec 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.43%
|
474,866
|
$1,666,780 | — | 31 Dec 2025 | |
| Mark Andrew White |
3/4/5
|
General Manager, Commercial Affairs |
—
mixed-class rows
|
101,867
mixed-class rows
|
$1,560,177 | — | 31 Oct 2024 | |
| Syed Ali-Aamir Rizvi |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
500,911
mixed-class rows
|
$1,549,921 | — | 11 Feb 2026 | |
| Susquehanna Portfolio Strategies, LLC |
13F
|
Company |
0.4%
|
434,409
|
$1,524,776 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.39%
|
421,174
|
$1,478,321 | — | 31 Dec 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.37%
|
400,706
|
$1,406,478 | — | 31 Dec 2025 | |
| FMR LLC |
13F
|
Company |
0.36%
|
395,275
|
$1,387,417 | — | 31 Dec 2025 | |
| M28 Capital Management LP |
13F
|
Company |
0.35%
|
385,680
|
$1,353,737 | — | 31 Dec 2025 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.32%
|
348,803
|
$1,224,299 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for ROCKET PHARMACEUTICALS, INC.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| John Militello | RCKT | Common Stock | Sale | -1.26% | $3,862 | $3.34 | -1,157 | 91,019 | 18 Feb 2026 | Direct |
| Gaurav Shah | RCKT | Common Stock | Sale | -0.57% | $19,995 | $3.34 | -5,990 | 1,046,055 | 18 Feb 2026 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -0.2% | $4,593 | $3.34 | -1,376 | 682,000 | 18 Feb 2026 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -1.76% | $40,582 | $3.31 | -12,253 | 683,376 | 13 Feb 2026 | Direct |
| John Militello | RCKT | Common Stock | Sale | -3.89% | $12,341 | $3.31 | -3,726 | 92,176 | 13 Feb 2026 | Direct |
| Gaurav Shah | RCKT | Common Stock | Sale | -1.15% | $40,668 | $3.31 | -12,279 | 1,052,045 | 13 Feb 2026 | Direct |
| Gaurav Shah | RCKT | Common Stock | Award | 36.8% | 286,028 | 1,064,324 | 11 Feb 2026 | Direct | ||
| Gaurav Shah | RCKT | Stock Option (Right to Buy) | Award | 870,648 | 870,648 | 11 Feb 2026 | Direct | |||
| John Militello | RCKT | Common Stock | Award | 45.5% | 29,982 | 95,902 | 11 Feb 2026 | Direct | ||
| John Militello | RCKT | Stock Option (Right to Buy) | Award | 45,018 | 45,018 | 11 Feb 2026 | Direct | |||
| Martin Louis Wilson | RCKT | Common Stock | Award | 81.2% | 311,813 | 695,629 | 11 Feb 2026 | Direct | ||
| Martin Louis Wilson | RCKT | Stock Option (Right to Buy) | Award | 468,187 | 468,187 | 11 Feb 2026 | Direct | |||
| Syed Ali-Aamir Rizvi | RCKT | Common Stock | Award | 17.9% | 61,963 | 407,874 | 11 Feb 2026 | Direct | ||
| Syed Ali-Aamir Rizvi | RCKT | Stock Option (right to buy) | Award | 93,037 | 93,037 | 11 Feb 2026 | Direct | |||
| Christopher James Stevens | RCKT | Common Stock | Award | 15.2% | 61,963 | 469,129 | 11 Feb 2026 | Direct | ||
| Christopher James Stevens | RCKT | Stock Option (Right to Buy) | Award | 93,037 | 93,037 | 11 Feb 2026 | Direct | |||
| Sarbani Chaudhuri | RCKT | Common Stock | Award | 79.1% | 125,924 | 285,160 | 11 Feb 2026 | Direct | ||
| Sarbani Chaudhuri | RCKT | Stock Option (Right to Buy) | Award | 189,076 | 189,076 | 11 Feb 2026 | Direct | |||
| Elisabeth Bjork | RCKT | Common Stock | Purchase | 25% | $34,400 | $3.44 | 10,000 | 50,000 | 02 Jan 2026 | Direct |
| Jonathan David Schwartz | RCKT | Common Stock | Sale | -0.84% | $7,592 | $2.98 | -2,545 | 299,064 | 18 Nov 2025 | Direct |
| John Militello | RCKT | Common Stock | Sale | -1.62% | $3,240 | $2.98 | -1,086 | 65,920 | 18 Nov 2025 | Direct |
| Gaurav Shah | RCKT | Common Stock | Sale | -0.8% | $18,721 | $2.98 | -6,276 | 778,296 | 18 Nov 2025 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -0.43% | $4,910 | $2.98 | -1,646 | 383,816 | 18 Nov 2025 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Award | 35% | 100,000 | 385,462 | 03 Nov 2025 | Direct | ||
| John Militello | RCKT | Common Stock | Sale | -30.2% | $114,581 | $3.96 | -28,918 | 67,006 | 14 Oct 2025 | Direct |
| Syed Ali-Aamir Rizvi | RCKT | Common Stock | Award | 345,911 | 345,911 | 06 Oct 2025 | Direct | |||
| Syed Ali-Aamir Rizvi | RCKT | Stock Option (right to buy) | Award | 383,854 | 383,854 | 06 Oct 2025 | Direct | |||
| Peter Fong | RCKT | Common Stock | Award | 53,333 | 53,333 | 24 Sep 2025 | Direct | |||
| Rtw Investments, Lp | RCKT | Common Stock | Other | -5.7% | -1,100,000 | 18,188,457 | 19 Sep 2025 | See footnote | ||
| Rtw Investments, Lp | RCKT | Common Stock | Exercise of in-the-money or at-the-money derivative security | 6.08% | 1,100,000 | 19,188,457 | 19 Sep 2025 | See footnote | ||
| Rtw Investments, Lp | RCKT | Equity Swap (obligation to buy) | Exercise of in-the-money or at-the-money derivative security | -100% | -3 | 0 | 19 Sep 2025 | See footnote | ||
| John Militello | RCKT | Common Stock | Award | 71.5% | 40,000 | 95,924 | 08 Sep 2025 | Direct | ||
| Martin Louis Wilson | RCKT | Common Stock | Award | 110.7% | 150,000 | 285,462 | 08 Sep 2025 | Direct | ||
| Jonathan David Schwartz | RCKT | Common Stock | Award | 36.1% | 80,000 | 301,609 | 08 Sep 2025 | Direct | ||
| Elisabeth Bjork | RCKT | Common Stock | Purchase | 33.3% | $34,100 | $3.41 | 10,000 | 40,000 | 27 Aug 2025 | Direct |
| John Militello | RCKT | Common Stock | Sale | -0.64% | $1,082 | $3.00 | -361 | 55,924 | 19 Aug 2025 | Direct |
| Jonathan David Schwartz | RCKT | Common Stock | Sale | -0.36% | $2,412 | $3.00 | -805 | 221,609 | 19 Aug 2025 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -0.43% | $1,762 | $3.00 | -588 | 135,462 | 19 Aug 2025 | Direct |
| John Militello | RCKT | Common Stock | Sale | -1.23% | $2,142 | $3.06 | -699 | 56,285 | 18 Aug 2025 | Direct |
| Jonathan David Schwartz | RCKT | Common Stock | Sale | -0.75% | $5,149 | $3.06 | -1,680 | 222,414 | 18 Aug 2025 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -0.73% | $3,077 | $3.06 | -1,004 | 136,050 | 18 Aug 2025 | Direct |
| Gaurav Shah | RCKT | Common Stock | Tax liability | -0.28% | -2,234 | 784,572 | 18 Aug 2025 | Direct | ||
| Jonathan David Schwartz | RCKT | Common Stock | Sale | -4.74% | $33,695 | $3.02 | -11,161 | 224,094 | 14 Aug 2025 | Direct |
| John Militello | RCKT | Common Stock | Sale | -11% | $21,263 | $3.02 | -7,043 | 56,984 | 14 Aug 2025 | Direct |
| Martin Louis Wilson | RCKT | Common Stock | Sale | -8.12% | $36,557 | $3.02 | -12,109 | 137,054 | 14 Aug 2025 | Direct |
| Christopher James Stevens | RCKT | Common Stock | Award | 407,166 | 407,166 | 04 Aug 2025 | Direct | |||
| Christopher James Stevens | RCKT | Stock Option (Right to Buy) | Award | 554,071 | 554,071 | 04 Aug 2025 | Direct | |||
| Aaron Ondrey | RCKT | Common Stock | Sale | -1.14% | $4,257 | $2.88 | -1,477 | 128,173 | 03 Jul 2025 | Direct |
| Piratip Pratumsuwan | RCKT | Common Stock | Award | 30,000 | 30,000 | 18 Jun 2025 | Direct | |||
| Pedro P. Granadillo | RCKT | Common Stock | Award | 54,734 | 54,734 | 18 Jun 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.